# US 5,705,401 A · Method of assaying for alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,705,401 A
- Document ID: US5705401A
- Status: Granted
- Kind: A
- Application number: 08/240,720
- Filed: 1994-09-16
- Granted: 1998-01-06
- Earliest claimed: 1991-11-12
- Assignees: The University of Melbourne
- Inventors: Colin Louis Masters; Ashley Ian Bush; Konrad Traugott Beyreuther
- Web page: https://patentgrep.com/patent/US5705401A

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G01N 2800/2821: Alzheimer
- Y10S 436/811: Test for named disease, body condition or organ function
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to a method of assaying for Alzheimer's disease in a human by determining the relative abundance of one or more forms of amyloid precursor protein (APP) or the enzyme responsible for said forms in circulatory fluid and to a method for treating the disease by modulating divalent cation, trivalent cation and/or heparin interaction with APP.

## Claims

### Claim 1

A method of assaying for probable Alzheimer's disease in a human which comprises determining in a sample of human circulatory fluid the amount of at least one of the 130 kDa form or 42 kDa form of amyloid precursor protein (APP) in said sample, wherein said APP is detected by Western blot with antibodies specific for at least one of the 130 kDa form or 42 kDa form of APP, comparing the levels of at least one of the 42 kDa form or the 130 kDa form in said sample to a normal control and correlating a significant increase in the 130 kDa form or a significant decrease in the 42 kDa form with the presence of Alzheimer's disease, wherein said 130 kDa form and 42 kDa form specifically binds to antibody 22C11.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the circulatory fluid is obtained after the human has undergone at least four hours of fasting.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the circulatory fluid is blood plasma.